This effect relies on IFNβ production in the tumor bed, readily visible a few hours after the first dose of poly A:U (15), which allows us to assume that CD103+ cDC1 and CD11b+ cDC2, are the initial source of IFNβ. The gene discussed is ITGAM; the disease is neoplasm.